GMP News, GMP guidelines, GMP Violations, GMP warnings A Public Health Global News Portal

Welcome to gmpviolations.com FDA, WHO, EU, TGA, CDSCO guidelines...and GMP Violations news/warning letters..

150000+ Industry Leaders already read it everyday

Wednesday, July 19, 2017

FDA Warning Letter | National Biological Corp | GMP Violations











The United States Food and Drug Administration (FDA) conducted an inspection at National Biological Corp a medical device operations firm at 23700 Mercantile Road, Beachwood, OH 44122, from March 6-20, 2017. 

During the inspection, an FDA investigator determined firm which manufacturer of UV phototherapy systems used to treat dermatological disorders. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.
 
This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We (FDA) received your response, dated April 6, 2017, concerning FDA investigator’s observations noted on the Form FDA 483, List of Inspectional Observations (FDA 483) that was issued to your firm As below.t These violations include, but are not limited to, the following: 

1)    Failure to validate a process whose results cannot be fully verified by subsequent inspection and test, as required by 21 CFR 820.75(a). Specifically,
 
a)  Two (b)(4) crimping press machines, five (b)(4) crimping applicator machines, and the (b)(4) crimping machine used to manufacture phototherapy devices have not been validated.
 
b)  The gluing/curing process used to manufacture the Dermalume 2x phototherapy device has not been validated.
 
Your response cannot be assessed at this time. Your response includes new validation procedures, protocol templates and a Validation Master Plan. Your plan states that the crimping processes and gluing & curing processes will be validated by June 30, 2017; all other processes requiring validation will be identified by June 30, 2017; the schedule, based on risk, will be established for all other processed that have been identified as requiring validation by August 30, 2017; and all validations will be completed by April 30, 2018.   Please provide an update on these corrective actions.
 
2)    Failure to establish and maintain procedures that address the identification, documentation, evaluation, segregation, and disposition of nonconforming product, as required by 21 CFR 820.90. 
 
a)  Specifically, your Nonconforming Material/Product procedures, QI-831 REV005, dated 02/27/2017 and QI-831 REV004, dated10/20/2016, do not assure all nonconformances receive an evaluation, which includes a determination of the need for an investigation. 
  • Nonconforming materials and products with a disposition of scrap, return to vendor or “use as is” are not evaluated to determine if an investigation is necessary. A total of 500 nonconformances with one of these three dispositions are listed in your 2016 NCR log and were not evaluated to determine if an investigations is necessary. 
b)  A total of 14 nonconformances listed in the 2016 NCM log do not have an initial or final disposition.
 
Your response is not adequate. Your response states the investigation conducted as part of CAPA 17-03 determined that your nonconformance procedure is inadequate in that it does not require an evaluation to determine if an investigation is necessary in all cases. You are revising your procedure and performing a retrospective review of all 2017 NCMs and remediating applicable investigations. A review of 4 months of records does not appear adequate. Typically, a 2 year retrospective review of records is performed. Please provide your rationale for reviewing only 4 months of records.
 
3)    Failure to establish and maintain procedures to assure that all complaints are reviewed and evaluated to determine whether an investigation is necessary, as required by 21 CFR 820.198(b).
 
Specifically, your Customer Complaint procedure, QI-853 Rev 001, dated 05/19/16 does not address evaluating all complaints to determine if an investigation is necessary, and complaints are only being assigned a complaint failure code and not being evaluated and investigated if there is a failure of the device.
 
Your response cannot be assessed at his time. Your response states that you will perform a retrospective review of the 2016 and 2017 complaint failure codes to determine if investigations are required. When required, investigations will be initiated and corrective actions taken. This review will be completed by June 1, 2017. Please provide an update on this corrective action.
 
4)    Failure to establish and maintain procedures for analyzing processes, work operations, concessions, quality audits, service records, complaints, returned product, and other sources of quality problems; and employing statistical methodology, where appropriate, to detect recurring quality problems, as required by 21 CFR 820.100(a).  
 
Specifically, complaint codes are assigned during the complaint evaluation but analysis of this data is not performed. Your Analysis of Data procedure, QI-841 Rev 000, was approved on 02/27/2017, but it has not been implemented.
 
Your response is not adequate. Your response states that you will perform a retrospective review of the 2016 and 2017 complaint failure codes to determine if investigations are necessary, but it does not address when you will be implementing your Analysis of Data procedure.
 
5)    Failure to have a complete risk analysis, as required by 21 CFR 820.30(g).
 
Specifically, potential hazards identified from post-market data for your phototherapy devices have not been incorporated into your risk analysis documents.
 
For example, Complaint 14107 describes a customer cutting their hand on your Handisol II photo-therapy device and Complaint 14426 describes a report of the external timer on the Dermalite therapy unit indicating hours and minutes instead of minutes and seconds. These hazards, sharp edges and incorrect timer readings, are not listed in the System Hazard Analyses Worksheet, PD-301, Rev 00, which is used to manage risk for these devices.
 
Your response cannot be assessed at this time. Your response provides documents showing that the hazards identified in the FDA-483 have been added to the appropriate risk analysis. You also state that the investigation conducted as part of CAPA 17-05 determined that your risk analysis procedures is inadequate. You state you will revise this procedure and will identify internal and external sources of post market data that require review for the risk management file. You also state that the last 12 months of complaints will be reviewed. Please provide the rationale for only reviewing 12 months of complaints to identify potential hazards that are not listed in your risk files. Also provide an update on the status of this corrective action.
 
6)    Failure to establish and maintain procedures to ensure that all purchased or otherwise received products and services conform to specified requirements, as required by 21 CFR 820.50. Specifically, Your Purchasing and Vendor Requirements procedure, QI-741, Rev 004, dated 11/3/2016, is inadequate in that :
 
a)  Consultants and contractors (test service lab) are not listed in your purchasing control procedures, and have not been evaluated; and requirements, including quality requirements have not been established, as required by 21 CFR 820.50.
 
b)  Quality requirements have not be established or evaluated for your high risk component suppliers, as required by 21 CFR 820.50(a). You have not required or evaluated processes at several suppliers that require validation of the process to manufacture the part/component. For example, parts/components have undergone processes such as injection molding, anodization and powder coating at the supplier and you do not require these processes be validated and have not included process validation during your evaluation.
 
c)  The type and extent of control has not been adequately defined for products based on evaluation results, as required by 21 CFR 820.50(a)(2). Specifically, your Purchasing and Vendor Requirements procedure does not describe the point values for any of your performance indicators nor does it describe the rating system associated with the assignment values.
 
d)  Consultants, testing services and off-the-shelf components used by your firm are not listed on your approved supplier list, as required by 21 CFR 820.50(a)(3).
 
Your response cannot be assessed at this time. Your response states you have opened CAPAs 17-06, 17-07 and 17-08 to investigate these violations. You are revising your procedures; reviewing the requirements for all suppliers; reevaluating critical suppliers; revising the monitoring and rating process for suppliers. Your response states all corrective actions will be completed by January 30, 2018. Please provide an update on the status of these corrective actions.
 
7)    Failure to document rework and reevaluation activities in the device history record, as required by 21 CFR 820.90(b)(2). Specifically,
 
A total of 3 of the 6 Nonconformance Reports that document rework for in-process nonconformances could not be linked to a device history record.
 
Your response cannot be assessed at this time. Your response states your investigation under CAPA 17-09 determined that rework is not being appropriately documented. The nonconforming product procedures and device history record procedure is being revised. The corrective action will be completed by June 30, 2017. Please provide an update on the status of these corrective actions.
 
8)    Failure to establish and maintain procedures to assure that equipment is routinely calibrated, inspected, checked and maintained, as required by 21 CFR 820.72(a).

www.gmpviolations.com GMP News, GMP guidelines, GMP Violations, GMP warnings, GMP Trends. A Public Health Global News Portal. (This story has not been edited by GMP Violations staff and is auto-generated from a syndicated feed/ experts experiences sharing.) Disclaimer: The Logos/Images & content posted here are belongs to respective to Authority / owners of firm. The Article posted under public health importance news. Please ensure the guideline as per Regulatory agencies.
Share:

0 comments:

Post a Comment

Related Posts Plugin for WordPress, Blogger...

AMAZON BEST DEALS

Popular Posts

AMAZON BEST DEALS

Subscribe Free GMP Guidelines

Enter your email address:

Delivered by FeedBurner

Followers

Printfriendly

Subscribe via email for free

Services

Enter your email address:

Delivered by FeedBurner

Contact Form

Name

Email *

Message *

Menu :
Powered by Blogger.

Visitors

    Translater

    Related Posts Plugin for WordPress, Blogger...

    Category

    2016 (37) 2017 (85) 2018 (9) 211 CFR (1) 211.63 (1) 483 (5) AAFA (1) Abbott (2) AboutUs (1) ALCOA (1) Alerts (2) ANDA (1) Anshu (2) Antibiotics (1) apic (1) APR17 (8) APS (2) Articles (4) AstraZeneca (1) Aug17 (2) Aurobindo (2) Author (2) Authors (8) Biocon (1) cadila (1) capa (3) CDSCO (5) Change control (1) Christian Green (1) cipla (2) Cleaning validation (1) Data Integrity (9) dec16 (15) Definations (1) Deviations (1) Donald Trump’s (2) Downloads (17) Dr.Reddy's (4) eca (1) EIR (1) Eli Lilly (1) ema (12) EU (9) FDA (70) FDA Guide (18) FEB17 (15) Genaral (1) General Health (2) GMP (1) GMP News (36) gsk (2) GuidelineEU (10) GuidelinesG (5) GuidelineW (2) GV/0117/001 (1) GVAuthors (3) Health (4) HOSPIRA (1) ICH (3) ICHGuide (3) import alert (1) India (1) ISPE (1) James Bullock (1) JAN17 (23) Jul17 (8) July17 (1) Jun17 (4) Lupin (2) Mahender (39) MAR17 (13) Mar18 (7) May17 (10) MHRA (3) MHRA guide (1) Mumbai (1) Mylan (4) Natco (1) News (55) Non Complinaces (1) Nov16 (5) Novartis (1) oct (1) Oct16 (10) OCT17 (1) PDA (1) Personnel (1) pfizer (1) pics (8) Picsguide (2) QbD (1) Quality Docs (1) RCA (1) Recall (1) safety (1) Sanjeev Kumar Singh (4) Sanofi (1) Sep16 (6) Siegfried Schmitt (2) SUN (1) TGA (3) TOP 10 PHARMA (1) USP (2) Validation (3) Warning Letters (43) WHO (6) zika (1)

    Sponsors

    Theme Support